Public trust is key to a successful immunisation programme.
A sports management scholar weighs in on the potential consequences of holding Big Ten football games in the fall instead of waiting for a vaccine or better safety procedures.
Several vaccines are in Phase 3 trials. So when will we know whether any of these will protect against COVID-19?
There's a targeted subunit protein vaccine, an mRNA vaccine, and a needle-free DNA vaccine. Here's what that all means.
Researchers rarely report what's in a placebo.
Will a vaccine for COVID-19 be safe? Animal testing, human clinical trials and post-approval surveillance give us good grounds to believe that a future approved vaccine will work and be safe.
The cold supply chain keeps vaccines fresh during distribution, but the current system is nowhere near large enough to distribute the billions of COVID-19 vaccines that the world needs.
A bioethicist explains a recent report that recommends how to distribute a COVID-19 vaccine equitably.
Governments must embrace policies that promote sharing and collective invention to create and distribute a vaccine quickly.
Wearing face masks may allow a tiny number of viral particles to slip through, possibly allowing our body to gain some sort of immunity.
From adenoviruses to RNA: the pros and cons of different COVID vaccine technologies
Malaria, tuberculosis and HIV/AIDS are regarded as the 'big three' infectious diseases. This is where scientists are at in their efforts to find a vaccine for each one.
Our best shot at ending the pandemic is by achieving herd immunity through widespread use of a vaccine. But that won't happen unless people believe it's safe.
A few people have developed COVID-19 twice. That doesn't mean a vaccine can't offer long-term protection.
Not all vaccines will work so well in all people. That's why we need large-scale clinical trials to test candidate vaccines in thousands of people.
Politics with Michelle Grattan: Jodie McVernon on Melbourne’s modelling, a Covid vaccine, and the role of experts in a crisis.
Michelle Grattan discusses the latest in coronavirus developments with Professor Jodie McVernon
The phase 3 trials of the University of Oxford/AstraZeneca vaccine have been paused because one participant became unwell. But we don't know for sure if the illness was a reaction to the vaccine.
The COVID-19 vaccine is in the final stages of testing – meaning we should know whether it's effective before the end of the year.
The Australian government is working with two major pharmaceutical companies to facilitate the local production and supply of two different COVID-19 vaccines – if they're proven to be effective.
Nanotechnology has an impressive record against viruses.